Industry: Pharmaceuticals (See others in industry)
Address:| Date | FilingType | Incremental Cash | Link to Raw Filing | |||
|---|---|---|---|---|---|---|
| 2025-06-20 | New | $2,314,800 | $2,314,800 | Other | 06c | SEC link |
| 2025-01-22 | New | $2,246,500 | $2,246,500 | Equity Only | 06b | SEC link |
| 2024-12-06 | New | $227,127 | $227,127 | Other | 06b | SEC link |
| 2024-10-04 | Amended | $205,480 | $0 | Other | 06b | SEC link |
| 2024-08-22 | New | $205,480 | $205,480 | Other | 06b | SEC link |
| 2021-08-05 | New | $30,000,000 | Unknown | Other | SEC link |
| Name | Role |
|---|---|
| Mark J. Gilbert | Director |
| William B. Hayes | Director |
| Hila Karah | Director |
| Hoonmo Lee | Director |
| Walt A. Linscott | Executive |
| Anthony J. Maddaluna | Director |
| Robert E. Martell | Director |
| Jeffrey A. Meckler | Director, Executive |
| Michael J Newman | Director, Executive |
| Brian O'callaghan | Director |
| Roger J. Pomerantz | Director |
| Nir Sassi | Executive |
| Roger J. Waltzman | Executive |